Safety data
| Safety | US-NB | US-P&F | AGSB | Total | P values |
| Biopsy procedures, n (%) | 402 (76.7) | 65 (12.4) | 57 (10.9) | 524 (100.0) | |
| Syncope or presyncope, n (%) | 2 (0.8) | 0 (0.0) | 0 (0.0) | 2 (0.4) | |
| Tenosynovitis | 1 (0.3) | 0 (0.0) | 0 (0.0) | 1 (0.2) | |
| Neurological disturbance*, n (%) | 4 (1.0) | 0 (0.0) | 0 (0.0) | 4 (1.0) | |
| Tendon damage, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Haemarthrosis, n (%) | 1 (0.3) | 0 (0.0) | 0 (0.0) | 1 (0.2) | |
| Deep vein thrombosis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Joint infection | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Total adverse events | 8 | 0 | 0 | 8 | 0.55† |
*Sensory impairment following biopsy, no motor involvement.
†Test for difference in total number of adverse events in each group, by Fishers exact.
AGSB, arthroscopic-guided synovial biopsy; US-NB, ultrasound-guided needle biopsy; US-P&F, ultrasound-guided portal and forceps.